Herceptin News and Research

RSS

Herceptin may work better when it is followed by injections of interleukin

A new study suggests that antibody-based cancer drugs might help patients more if they are given with substances that stimulate the immune system.

5 Jan 2006

A good year for breast cancer detection and treatment

It was a good year in women’s health, notably breast cancer treatment and detection. The December issue of Mayo Clinic Women’s HealthSource hails these important advances of 2005.

29 Dec 2005

Targeted cancer therapies: Another step forward

While it is clear that the treatment of cancer has already begun to undergo a paradigm shift with the inclusion of innovative targeted therapies into current regimens, it would be wrong to assume these products will entirely replace traditional chemotherapy as the standard treatment for cancer sufferers.

22 Dec 2005

Targeted cancer therapies: Another step forward

22 Dec 2005

Gene mapping project promises new targeted cancer therapies

Government researchers in the United States have this week launched a pilot project to find all the little genetic changes that cause cancer in the hope it will lead to a whole new world of targeted cancer therapy.

14 Dec 2005

NHS under pressure to provide new breast cancer drugs

The National Health Service in the UK is being put under considerable pressure by Cancer charities to widen access to a promising new class of breast cancer drug as new evidence suggests the latest treatment is far superior to Tamoxifen, the long established premier drug for women with the early stage of the disease.

12 Dec 2005

Herceptin - can healthcare afford this expensive drug?

New research into the cost of using the breast cancer drug Herceptin warns that healthcare authorities and the organisations advising them should not rush to prescribe it for early breast cancer without working out extremely carefully the budget implications and cost-effectiveness of the drug.

2 Dec 2005

Difficult decisions ahead over Herceptin breast cancer drug

According to Belgian researchers a drug prescribed for women with advanced breast cancer would be cost-effective for treating some, but not all patients, in the early stages of the disease.

30 Nov 2005

Tamoxifen reduces long-term risk of cancer

According to a new study released this week, women at high risk for breast cancer who take the well-known drug Tamoxifen, can reduce their long-term risk of developing the disease.

16 Nov 2005

Cannabis-based medicine given go-ahead to treat MS patients

Sufferers in the UK from multiple sclerosis and possibly rheumatoid arthritis, will welcome the news that they will soon be able to obtain an unlicensed, cannabis-based medicine on prescription to treat their illness.

16 Nov 2005

Lancet warns Herceptin breast cancer drug 'over hyped'

The Lancet medical journal which is both influential and well respected, has cast some doubt on the claims that Herceptin was "a cure" for breast cancer and has attacked the hype surrounding the treatment by the Government and the media.

10 Nov 2005

Refusal to give new breast cancer drug lands health authority in court

British health secretary Patricia Hewitt has become embroiled in a row over the provision of the revolutionary breast cancer drug Herceptin.

9 Nov 2005

Herceptin results beg questions on equal access to expensive drugs

The recent press coverage on the use of Herceptin (brand name for the drug trastuzumab) for treating breast cancer in its early stages shows that issues of equal access to costly but effective drugs must be confronted, says an editorial in the British Medical Journal.

7 Nov 2005

Substance found in evening primrose oil inhibits breast cancer gene

Gamma-linolenic acid (GLA), a substance in evening primrose oil and several other plant oils used in herbal medicine, inhibits action of Her-2/neu, a cancer gene that is responsible for almost 30 percent of all breast cancers, Northwestern University researchers report.

3 Nov 2005

First study to confirm the benefit of anti-angiogenic therapy in patients with breast cancer

Results from the first and only interim analysis of an important trial assessing the potential of Herceptin (trastuzumab) to improve disease-free survival (DFS) in HER-2 positive breast cancer patients after adjuvant chemotherapy, have shown that Herceptin affords a significant survival advantage.

1 Nov 2005

Way now clear for use of costly breast cancer drug throughout UK

Health managers in the UK have virtually been ordered to pay for the drug Herceptin for women with an aggressive form of breast cancer in its early stages.

26 Oct 2005

New treatments suggest that cancer is on the run!

People suffering from cancer will be encouraged by a cluster of recent reports on successful new treatments for several different forms of cancer.

24 Oct 2005

Breast cancer drug Herceptin a 'stunner'

According to the New England Journal of Medicine (NEJM) the first trials of the breast cancer drug, Herceptin, tested on women with early stage disease are "simply stunning".

20 Oct 2005

Herceptin results "quite remarkable"

The targeted drug trastuzumab, or Herceptin, previously shown to prolong survival in advanced breast cancer, dramatically reduced the chances of recurrence in patients with early-stage disease when given for one year following standard chemotherapy.

19 Oct 2005

Herceptin therapy highly superior to standard breast cancer treatment

In a joint paper, co-authored by Mayo Clinic's Edith Perez, M.D., and Edward Romond, M.D., of the National Surgical Adjuvant Breast and Bowel Project (NSABP), researchers report complete and combined results of two trials comparing adjuvant chemotherapy with or without concurrent trastuzumab treatment in women with surgically removed HER2-positive breast cancer.

19 Oct 2005